CD276 and lung cancer: In non-small cell lung cancer (NSCLC), which accounts for a substantial majority of lung cancer cases, the prevalence of tumors exhibiting upregulated B7-H3 expression is reported to range from 32% to 70%, depending on the study cohort and the methodologies employed for expression assessment [119,120].